Nektar Therapeutics

Background

Company Name	Nektar Therapeutics
Stock Symbol	NKTR
Class Period	February 26, 2025 to December 15, 2025
Lead Plaintiff Motion Deadline	May 05, 2026

Submit Your Information

If you suffered a loss on your Nektar Therapeutics investments or would like to inquire about joining an action to recover your loss under the federal securities laws, please complete the form below. Please note that submission of this form does not by itself form an attorney-client relationship nor does filling out this form mean you have joined any lawsuit.

First Name*

Middle Initial

Last Name*

Email*

Phone*

If representing a Corporation, Trust, Partnership or other entity, Name of Entity

If representing an Entity, Position at Entity

Mailing Address

City

State/Province

ZIP/Postal Code

Country

Are you a current or former employee of the company?

Did you purchase any shares before February 26, 2025?

Shares Purchased

Number of Shares	Buy Date	Price Per Share	Add
Purchased quantity	Purchased month Purchased day Purchased year

Shares Sold

Number of Shares	Sell Date	Price Per Share	Add
	Sold month Sold day Sold year

Additional Comments

Background

On December 16, 2025, Nektar announced “topline results from the 36-week induction treatment period of the Phase 2b REZOLVE-AA trial of” its alopecia areata treatment, rezpegaldesleukin, disclosing that the trial failed to reach statistical significance, which Nektar attributed to the inclusion of four patients who should not have been eligible to participate.

On this news, Nektar’s stock price fell $4.14, or 7.8%, to close at $49.16 per share on December 16, 2025, thereby injuring investors.

The complaint filed in this class action alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company’s business, operations, and prospects. Specifically, Defendants failed to disclose to investors that: (1) enrollment in the REZOLVE-AA trial had not followed applicable instructions and protocol standards; (2) the foregoing was likely to have a significant negative impact on the REZOLVE-AA trial’s results; (3) accordingly, the REZOLVE-AA trial’s overall integrity and prospects were overstated; and (4) as a result, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis at all relevant times.

Submit Your Information